Creo Medical has developed its Cool Plasma technology, which has been shown to be highly effective in killing bacteria, with a 99.99% kill rate on tough bacteria such as MRSA, E. coli and C. difficile. Initial testing has shown it to be effective in inactivating the Covid-19 virus. The company believes it could be very useful in decontaminating and sterilising medical equipment, such as PPE and ventilators, and cleaning and sterilising hospital wards, ambulances, and other enclosed spaces, as well as for sterilising wounds.
Carterra® Inc., the world leader in high-throughput antibody screening and characterization, has announced the availability of a highly accurate assay for simultaneously measuring the concentration and binding of IgG, IgM, and IgA antibodies to the Receptor Binding Domain (RBD) of SARS-CoV-2. Carterra’s new label-free assay provides, for the first time, detailed resolution of the immune response of patients recovering from COVID-19 in a single assay...
Edinburgh-based biotech company Ingenza Ltd. has made a significant breakthrough in the race to develop and manufacture a cost-effective vaccine against SARS-CoV-2, the virus responsible for the current COVID-19 pandemic. Ingenza has been working closely with researchers at Oxford University and the UK CPI, Wilton, since the start of the outbreak, and the collaboration is continuing to make excellent progress...
Absolute Antibody Ltd., an industry-leading provider of recombinant antibody products and services, has announced the availability of SARS-CoV-2 neutralizing antibodies derived from individuals infected with COVID-19. The antibodies, originally generated by Fred Hutchinson Cancer Research Center, have been engineered into recombinant formats useful for COVID-19 research and diagnostic development....
Intravacc and the Celonic Group has announced that they have signed a research agreement to further design, develop and produce a Covid-19 vaccine based on an immunogenic Spike (S) protein of SARS-CoV-2 combined with Intravacc’s prorietary Outer Membrane Vesicle (OMV) technology. In the beginning of March this year Intravacc started working on the development of four candidate coronavirus vaccines...
This year, in addition to the academic year course ‘Honors Computational Medicinal Chemistry’, 80 rising juniors and seniors will embark upon a special summer short-course entitled ‘Computing COVID-19’, utilizing StarDrop in conjunction with other bioinformatics tools. Optibrium’s lead product, StarDrop, is a comprehensive suite of integrated software...
Avacta Group plc, the developer of Affimer® biotherapeutics and reagents, is pleased to announce that it has entered into a collaboration with the Liverpool School of Tropical Medicine (“LSTM”) to clinically validate the rapid, saliva-based coronavirus antigen test that Avacta is developing with Cytiva. LSTM has been at the forefront of research into infectious, debilitating and disabling diseases since 1898....
Absolute Antibody Ltd., an industry-leading provider of recombinant antibody products and services, has announced a partnership with University of Zurich to offer synthetic nanobodies against the receptor binding domain (RBD) of SARS-CoV-2, the coronavirus that causes COVID-19. Under the partnership, the original nanobodies and newly engineered formats are now available to the global research community for use as serological controls and in COVID-19 therapeutic development....
LGC SeraCare is pleased to announce that the AccuPlex™ SARS-CoV-2 Reference Material Kit v2 is now CE-marked for in vitro diagnostic use (CE-IVD). With this change in regulatory status, the new product name is AccuPlex SARS-CoV-2 Molecular Controls Kit. Bearing the CE mark and IVD symbol signifies that the AccuPlex SARS-CoV-2 Molecular Controls Kit meets extensive design control requirements....
Tackling a pandemic is a massive effort that calls people from disciplines far and wide. Politicians, public figures and, of course, medical staff are all deeply involved in the response. Hidden just behind the front lines, however, are laboratories that are working to bring these unprecedented times to an end. Here, Lab Innovations 2020 hears from Anthony Cooke, CEO of Cambridge Clinical Laboratories...
The COVID-19 rapid antibody test, developed by Abingdon Health, the medical device manufacturer leading the UK-Rapid Test Consortium (UK-RTC), has received its CE mark. This means it is approved for professional use in the UK and EU. This milestone means the rapid test, for detection of IgG antibodies to the SARS-CoV-2 virus (COVID-19) is now available for distribution for professional use....
Empirical Bioscience announce that their QuantiTASE and QuantiTASE PLUS One Step RT-qPCR RT-qPCR Kits have been successfully tested in assays using EUA authorized qPCR detection kits using the established CDC testing protocol. The test amplifies and identifies genetic material from the SARS-CoV-2 virus that causes COVID-19 in one step. The QuantiTASE RT-qPCR Assay Kits works by converting the CoV-2 RNA into DNA and amplifying to detect the presence of pathogenic material in patient samples....
Avacta Group plc, the developer of Affimer® biotherapeutics and reagents, is pleased to announce that it has entered into a collaboration with Integumen plc to evaluate recently generated Affimer reagents that bind the SARS-COV-2 spike protein for the detection of the coronavirus in waste water, to provide a real-time alert system to warn of localised COVID-19 outbreaks...
A team of scientists at the University of Glasgow has identified a cat in the UK that was infected with SARS-CoV-2, the virus that causes COVID-19. Researchers from the MRC-University of Glasgow Centre for Virus Research (CVR) in partnership with the Veterinary Diagnostic Service (VDS) of the University’s School of Veterinary Medicine made the discovery as part of their joint research programme...
An article in the June 18, 2020 edition of the journal Nature Biotechnology details a timely project at the University of California, Berkeley: how to create a CLIA-certified COVID-19 testing lab from a research lab, in only three weeks. Read more about how we radically reduced a 6-12 month timeline....
AMSBIO has launched a range of ready-to-use SARS-CoV-2 Spike protein coupled magnetic beads that combine convenience, minimum non-specific binding and developed operational protocols saving you time and hassle. Developed for immunocapture, cell stimulating, biopanning and flow cytometry applications these new products use biotinylated SARS-CoV-2 Spike protein pre-coupled to streptavidin conjugated magnetic beads, which can capture the Anti-SARS-CoV-2 antibody or ACE2 protein from cell or serum sample....
Avacta Group plc, the developer of Affimer® biotherapeutics and reagents, is pleased to announce that it has begun work with the UK government’s CONDOR programme to evaluate and clinically validate the high throughput COVID-19 bead-assisted mass spectrometry (“BAMS™”) laboratory assay developed with Adeptrix. The COVID-19 National Diagnostic Research and Evaluation Platform (CONDOR), recently funded by the National Institute for Health Research...
New England Biolabs® (NEB®) has announced the launch of the SARS-CoV-2 Rapid Colorimetric LAMP Assay Kit, a Research Use Only (RUO) product that can be used for the detection of novel coronavirus, SARS-CoV-2 RNA. The kit serves as a simple alternative to RT-qPCR and enables visual detection of amplification of SARS-CoV-2 nucleic acid in just 30 minutes. 
PerkinElmer, Inc.